<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345421</url>
  </required_header>
  <id_info>
    <org_study_id>LAL-CSS01</org_study_id>
    <nct_id>NCT02345421</nct_id>
  </id_info>
  <brief_title>A Study to Identify and Characterize LAL-D Patients in High-risk Populations</brief_title>
  <official_title>A Study to Identify the Frequency of Lysosomal Acid Lipase Deficiency in At-Risk Patient Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency&#xD;
      (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in patients who are considered&#xD;
      to be at risk.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>LAL D frequency based on LAL enzyme assay.</measure>
    <time_frame>approximately 1 month</time_frame>
    <description>The endpoint of this study is the frequency of LAL D in at-risk patients, based on results from the LAL enzyme assay.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">640</enrollment>
  <condition>Lysosomal Acid Lipase Deficiency</condition>
  <arm_group>
    <arm_group_label>At risk population</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients &gt;2 years of age who are at risk for a diagnosis of LAL D&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-obese** patients with elevated low-density lipoprotein (LDL)&#xD;
&#xD;
          2. Non-obese** patients with low high-density lipoprotein (HDL)&#xD;
&#xD;
          3. Non-obese** patients with unexplained and persistently elevated liver transaminases,&#xD;
&#xD;
          4. Non-obese** patients with hepatomegaly&#xD;
&#xD;
          5. Patients with cryptogenic cirrhosis&#xD;
&#xD;
          6. Patients with biopsy-proven microvesicular or mixed micro/macrovesicular steatosis&#xD;
             without a known etiology&#xD;
&#xD;
          7. Patients with presumed Familial Hypercholesterolemia (FH) in which genetic analysis&#xD;
             was performed for the genes encoding the low-density lipoprotein receptor (LDLR),&#xD;
             Apo-B and PCSK9 genes and no disease-causing mutations were identified&#xD;
&#xD;
          8. Patients with presumed FH with unclear family history&#xD;
&#xD;
          9. Patients with autosomal recessive hypercholesterolemia (other than homozygous FH)&#xD;
&#xD;
         10. Patients with autosomal recessive low HDL of unknown etiology&#xD;
&#xD;
        Also, patient must meet the following:&#xD;
&#xD;
          -  Patient or patient's parent or legal guardian (if applicable) consents to participate&#xD;
             in the study and provides informed consent prior to any study procedures being&#xD;
             performed. If the patient is of minor age; he/she is willing to provide assent where&#xD;
             required per local regulations, and if deemed able to do so.&#xD;
&#xD;
          -  Patient is willing and able to comply with protocol requirements.&#xD;
&#xD;
          -  Patients who do not fall into one of the aforementioned categories (cohorts) but are&#xD;
             considered highly suspicious for LAL D should be tested to rule out the disorder&#xD;
             outside of the study at the discretion of the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active viral hepatitis;&#xD;
&#xD;
          -  Other confirmed genetic liver diseases (e.g., Wilson's disease, hemochromatosis, alpha&#xD;
             1-antitrypsin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LAL D</keyword>
  <keyword>CESD</keyword>
  <keyword>NASH</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Wilson's</keyword>
  <keyword>Niemann Pick</keyword>
  <keyword>Familial Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wolman Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

